Henry Schein Marks 20th Anniversary of Practice Pink Initiative
Henry Schein is celebrating the 20th anniversary of its Practice Pink initiative, a global program supporting cancer research and prevention. The initiative, which collaborates with healthcare professionals, supplier partners, and nonprofit organizations, has contributed over $2.1 million to cancer-related causes worldwide. Practice Pink is part of Henry Schein Cares, the company's global corporate citizenship program, which is marking its 25th anniversary this year.
Henry Schein expands credit line while analysts rate Henry Schein stock Moderate Buy
Henry Schein expanded its revolving credit commitments from USD 1.00 billion to USD 1.25 billion, providing the company with additional financial flexibility. This move comes as analysts rate the stock a "Moderate Buy" and the company reports strong second-quarter growth, supporting its raised sales-growth guidance for fiscal 2026. The expanded credit facility will support working capital, capital expenditures, share repurchases, refinancing, and potential acquisitions, aligning with Henry Schein's value creation program.
Henry Schein stock reflects raised 2026 guidance
Henry Schein's stock performance is linked to its raised fiscal 2026 guidance, driven by strong second-quarter revenue of USD 3.46 billion. The company increased its sales growth guidance to 4.5%-5.5% and non-GAAP diluted EPS guidance to USD 5.29-5.39, supported by increased operating margins and cash flow. Analysts maintain a "Moderate Buy" consensus with a target price above the current stock value, emphasizing execution against the new outlook.
Palvella Therapeutics Inc (PVLA-Q) Stock Price and News
This article provides stock information and news headlines for Palvella Therapeutics Inc. (PVLA-Q). It includes real-time stock data, analyst ratings, earnings call transcripts, and insights into the company's progress with its QTORIN product and Nasdaq uplisting. Palvella Therapeutics is a clinical-stage biopharmaceutical company focused on rare genetic skin diseases.
Dental Equipment & Technology Stocks Q2 Earnings Review: Envista (NYSE:NVST) Shines
Envista (NYSE:NVST) led the dental equipment and technology sector in Q2 earnings, reporting a 7.1% year-on-year revenue increase to $730.5 million, exceeding analysts' expectations. Despite strong financial performance from several companies, the sector's stock prices generally declined post-earnings, with Envista down 18.2% and Align Technology (NASDAQ:ALGN) showing the weakest performance against estimates. The article also touches upon market uncertainties, from AI's impact to geopolitical tensions, influencing investor sentiment.
Henry Schein Cares Marks 25 Years of Helping Health Happen®
Henry Schein Cares, Henry Schein, Inc.'s global corporate citizenship program, is celebrating 25 years of promoting health through partnerships and initiatives. The program, which has contributed over $285 million in cash and donated products, focuses on five interconnected pillars: Catalyzing Healthcare Access, Advancing Policies, Solutions & Innovations, Relationship Building for Change, Empowering Team Schein, and Sustaining the Planet. Moving forward, Henry Schein Cares plans to expand access to care for vulnerable populations, advance dental-medical integration, and strengthen disaster preparedness.
Henry Schein Cares Marks 25 Years of Helping Health Happen®
Henry Schein Cares, the global corporate citizenship program of Henry Schein, Inc., is celebrating its 25th anniversary. The program, which has contributed over $285 million in cash and donated products since 2001, focuses on five interconnected pillars: Catalyzing Healthcare Access, Advancing Policies, Solutions & Innovations, Relationship Building for Change, Empowering Team Schein, and Sustaining the Planet. Henry Schein reaffirmed its commitment to building a healthier future by expanding access to care, promoting prevention, and supporting healthcare professionals and environmental sustainability.
Henry Schein stock: company announces conference presentation and distribution agreement
Henry Schein (Nasdaq: HSIC) announced it will present at the Baird Global Healthcare Conference on September 15, 2026. Separately, the company entered into a distribution agreement with Applied BioCode to distribute its BioCode MDx-3000 System and associated assays to healthcare providers nationwide.
Raised guidance supports Henry Schein stock after Q2 beat
Henry Schein (HSIC) stock is supported by raised guidance after the company reported strong Q2 2026 results, with sales up 6.7% to $3.5 billion and adjusted EPS increasing 15.5% to $1.27. The company also expanded its revolving credit commitments to $1.25 billion, enhancing strategic flexibility. Analysts maintain a "Moderate Buy" consensus with a price target above the current stock price.
Henry Schein stock reflects raised 2026 guidance at USD 86.37
Henry Schein stock is trading at $86.37 after the company raised its fiscal 2026 sales growth guidance to 4.5%-5.5% and adjusted diluted EPS guidance to $5.29-$5.39. This follows strong Q2 2026 sales of $3.46 billion, up 6.7% year-over-year. Analysts have a "Moderate Buy" consensus with an average 12-month price target of $92.93, indicating potential upside from the current price.
Henry Schein Inc Lobbying Profile, 2011
This article provides a lobbying profile for Henry Schein Inc. for the year 2011, detailing their federal lobbying expenditures. The data, compiled by OpenSecrets from Senate Office of Public Records, shows Henry Schein Inc. spent $140,000 on direct lobbying efforts during the first half of 2026. The page outlines sections such as a summary, hired firms, lobbyists, issues, agencies, and bills related to their lobbying activities.
Q2 Rundown: Dentsply Sirona (NASDAQ:XRAY) Vs Other Dental Equipment & Technology Stocks
This article analyzes the Q2 performance of several dental equipment and technology stocks, highlighting Dentsply Sirona (XRAY), Envista (NVST), Align Technology (ALGN), and Henry Schein (HSIC). It details their revenue growth, performance against analyst estimates, and stock price reactions, noting that the sector experienced strong Q2 revenues but subsequent stock price declines. The piece also touches on broader market shifts, including concerns over AI and geopolitics impacting investor focus.
Henry Schein Q2FY26 Results: Non-GAAP EPS up 15.5%, guidance raised
Henry Schein reported strong Q2 FY26 results, with non-GAAP EPS increasing 15.5% to $1.27 and global sales rising 6.7% to $3.5 billion. The company raised its full-year FY26 guidance for sales growth to 4.5%-5.5% and non-GAAP diluted EPS to $5.29-$5.39, driven by strong segment performance and strategic initiatives like expanding AI-enabled capabilities. This growth was fueled by operational efficiency, with high-margin businesses now contributing nearly 50% of total operating income.
Is Henry Schein Stock Outperforming the Dow?
Henry Schein, Inc. (HSIC) is outperforming the Dow Jones Industrials Average ($DOWI) year-to-date and over the past 52 weeks, driven by strong internal sales, dental merchandise gains, and strategic acquisitions. The company's Q2 results exceeded Wall Street expectations for both EPS and revenue, contributing to a "Moderate Buy" rating from analysts. HSIC continues to focus on digital transformation and long-term growth through its BOLD+1 plan and investments in technology.
Transcript: Henry Schein Q2 2026 Earnings Conference Call
Henry Schein Inc. reported strong Q2 2026 financial results with significant sales and non-GAAP EPS growth, leading to an increased full-year guidance. The company highlighted strategic initiatives including AI-enabled technology platforms, accelerated sales of own-brand products, and medical business expansion. Value creation efforts are on track to achieve $200 million in operating income improvements, with a focus on enhancing customer experience and driving sustainable shareholder value.
Henry Schein stock trades below its yearly high after Q2 figures
Henry Schein stock traded at USD 85.53 on September 24, 2026, remaining below its 52-week high of USD 92.18, despite strong second-quarter results. The company reported a 15.5% increase in adjusted diluted EPS to USD 1.27 and raised its full-year 2026 adjusted EPS guidance to USD 5.29-5.39. Henry Schein also increased its revolving credit agreement to USD 1.25 billion, enhancing financial flexibility.
Henry Schein stock heads into the open after closing at USD 85.05
Henry Schein stock closed at USD 85.05 on September 23, 2026, with a market valuation of USD 9.74 billion. The Nasdaq Composite saw a minor increase, while the S&P 500 and Dow Jones Industrial Average experienced declines on September 24, 2026. The next trading day, September 25, 2026, will be a reference point for Henry Schein's stock performance.
Henry Schein stock trades at USD 85.56 after Q2 guidance
Henry Schein stock (HSIC) traded at USD 85.56 on Nasdaq, up 0.60 percent, following its Q2 2026 earnings report and an expanded revolving credit facility. The healthcare distributor reported Q2 revenue of USD 3.46 billion and non-GAAP EPS of USD 1.27, a 15.5 percent increase year-over-year. The company also expanded its revolving credit facility to USD 1.25 billion, extending its maturity to September 2031, providing additional financial flexibility.
STERIS plc (Ireland) (STE) Stock forecasts
Argus has lowered its target price for STERIS plc (Ireland) (STE) to $230.00. STERIS is a medical technology company specializing in sterilization services and infection prevention. The report was published on September 23, 2026.
Henry Schein stock heads into the open after a 0.47 percent drop
Henry Schein stock (US42548G1040) closed at USD 87.02 on September 23, 2026, experiencing a 0.47 percent drop, while the Nasdaq Composite fell 1.1 percent. The stock traded between USD 86.34 and USD 87.94, outperforming the Nasdaq by 0.63 percentage points. Upcoming economic data on jobless claims, building permits, and new home sales could influence the stock due to potential effects on interest rates and market conditions.
Henry Schein stock falls 2.72 percent despite higher guidance
Henry Schein's stock dropped 2.72% on September 23, 2026, to USD 85.05, despite the healthcare distributor raising its 2026 outlook. The company reported Q2 2026 revenue of USD 3.458 billion, exceeding estimates, and adjusted diluted EPS of USD 1.27, also above consensus. Management increased its full-year 2026 total sales growth forecast to 4.5%-5.5% and non-GAAP diluted EPS to USD 5.29-5.39, indicating strong underlying operational growth.
Henry Schein stock gains 0.42 percent ahead of the open
Henry Schein stock gained 0.42 percent ahead of the open on September 23, 2026, after closing at USD 85.20 on Nasdaq the previous day. The company also announced an expansion of its revolving credit facility by $250 million, increasing it to $1.25 billion, with the agreement running through September 19, 2031. This credit facility is intended to support working capital, capital expenditures, share repurchases, and potential acquisitions.
Henry Schein stock gains as credit facility expands
Henry Schein's stock saw a modest gain of 0.42% on September 22, 2026, closing at USD 85.20. The company recently expanded its revolving credit facility from USD 1.0 billion to USD 1.25 billion, extending its maturity to September 19, 2031. This increase in financial flexibility can support various corporate activities, although it does not directly impact current operating performance.
Henry Schein Expands Revolving Credit Facility to $1.25 Billion, Extends Maturity to 2031
Henry Schein (HSIC) has increased its revolving credit facility from $1.0 billion to $1.25 billion and extended its maturity to September 19, 2031. This expanded facility, led by JPMorgan Chase Bank, will be used to support working capital, capital expenditures, share repurchases, debt refinancing, and potential acquisitions, enhancing the company's liquidity. The agreement was finalized on September 21, 2026.
Henry Schein, Inc. (HSIC) Stock Analysis: A Promising 15.73% Upside in the Healthcare Sector
Henry Schein, Inc. (HSIC) is a leading healthcare sector player with a market capitalization of $9.66 billion, serving dental and medical practitioners globally. Despite a recent stable stock movement, analysts project a 15.73% potential upside, with positive sentiment due to its attractive valuation, robust revenue growth, and strategic focus on innovation. The company's decision not to distribute dividends allows it to reinvest in growth and technology, making it a stock worth watching for investors.
Envista launches Kerr dental consumables in India amid broader Asian expansion
Envista Holdings Corp. has launched Kerr consumables in India, marking the country as a strategic growth market due to increasing oral health awareness and demand for restorative treatments. This launch follows the opening of a new manufacturing facility in Suzhou, China, indicating Envista's broader focus on Asian expansion and increased regional production. The company plans to strengthen its presence in India through increased engagement with clinicians and educational initiatives.
Henry Schein stock holds near 52-week high as investors focus on 2026 EPS guidance
Henry Schein stock is trading near its 52-week high, with investors closely watching its fiscal year 2026 EPS guidance of $5.290 to $5.390. Analysts have a "Moderate Buy" consensus with an average price target of $92.93, indicating a potential upside of 5.2%. Institutional investors hold a significant portion of the company's shares, highlighting strong professional interest.
Henry Schein Inc Share Price - HSIC, RNS News, Articles, Quotes, & Charts (NASDAQ:HSIC)
This page provides an overview of Henry Schein Inc. (NASDAQ:HSIC), detailing its current market price, daily change, market capitalization, and 52-week high and low. It also offers a brief company profile, highlighting its role as a solutions provider for healthcare professionals across various sectors. The page includes a news archive showcasing past announcements and financial reports related to the company.
Tax withholding prompts Henry Schein (HSIC) insider to return shares
Henry Schein executive Andrea Albertini reported two share dispositions on September 8, 2026. Albertini surrendered 603 shares to Henry Schein to cover tax withholding related to the vesting of restricted stock units and disposed of an additional 3,984 shares directly back to the company without stated consideration. These transactions were not open-market trades nor made under a Rule 10b5-1 plan.
Henry Schein Executive Andrea Albertini Reports Two Stock Disposals on September 8, 2026
Henry Schein's CEO of Global Distribution and Technology, Andrea Albertini, reported two stock disposals on September 8, 2026. These transactions included surrendering 603 shares to cover tax withholdings from vested performance-based restricted stock units and disposing of an additional 3,984 shares at no cost. Following these disposals, Albertini directly holds 116,104 shares of Henry Schein common stock.
Precision Trading with Henry Schein Inc. (HSIC) Risk Zones
This article provides a detailed analysis of Henry Schein Inc. (HSIC) using AI models, offering precision trading strategies for different risk profiles and holding periods. It highlights a neutral near and mid-term outlook but a positive long-term bias, noting an exceptional 25.6:1 risk-reward setup. The analysis includes specific entry zones, targets, and stop losses for position, momentum breakout, and risk hedging strategies, along with multi-timeframe signal analysis.
Henry Schein Inc. stock outperforms competitors despite losses on the day
Shares of Henry Schein Inc. (HSIC) decreased by 1.06% to $88.86 on Tuesday, marking its second consecutive day of losses. Despite this, the stock outperformed the broader market, as the S&P 500 Index (SPX) fell by 0.58% and the Dow Jones Industrial Average (DJIA) fell by 1.18% during the same trading session.
Henry Schein to Present at Baird Global Healthcare Conference
Henry Schein, Inc., a leading provider of healthcare solutions, announced it will present at the Baird Global Healthcare Conference on September 15, 2026, at 12:15 p.m. EDT. The presentation will be available via live webcast on their investor relations website. Henry Schein is a FORTUNE 500 company providing products, services, and technology platforms to healthcare customers worldwide.
Henry Schein to Distribute Applied BioCode's MDx-3000 System in US
Henry Schein, Inc. has entered into a distribution agreement with Applied BioCode for its MDx-3000 System in the US. This partnership aims to expand the availability of Applied BioCode's diagnostic technology through Henry Schein's extensive distribution network. The article also provides a company profile for Henry Schein, detailing its business segments and financial performance.
Applied BioCode Announces Distribution Agreement with Henry Schein
Applied BioCode has announced a distribution agreement with Henry Schein to expand the availability of its BioCode® MDx-3000 System and molecular diagnostics menu. This partnership will allow Henry Schein to distribute the system and its assays to hospitals, health systems, and reference laboratories nationwide, enhancing access to advanced molecular diagnostic capabilities. The BioCode® MDx-3000 is an automated, high-throughput platform designed for high-complexity clinical laboratories, offering accurate and efficient testing.
Hsbc Holdings PLC Raises Position in TE Connectivity Ltd. $TEL
Hsbc Holdings PLC significantly increased its holdings in TE Connectivity Ltd. by 19.7% in the second quarter of 2026, bringing its total to 1.34 million shares valued at approximately $269.1 million. This comes as TE Connectivity exceeded quarterly earnings expectations, reporting $2.94 EPS and $5.16 billion in revenue, and announced a quarterly dividend of $0.78 per share. Analysts generally maintain a "Moderate Buy" rating for the stock, with an average price target of $251.15.
Henry Schein stock gains institutional support as new diagnostic partnership advances strategy
Henry Schein stock is trading near its 52-week high, bolstered by fresh institutional buying and a new distribution partnership for DermaSensor's FDA-cleared skin cancer device. This strategic move aligns with the company's focus on high-margin technology and specialty offerings, enhancing its growth story for healthcare investors. The company reported strong Q2 2026 earnings, and analysts maintain a "Moderate Buy" consensus, with several raising price targets, indicating positive sentiment for its future performance and strategic direction.
How Investors May Respond To Henry Schein (HSIC) Distributing DermaSensor’s Skin Cancer Detection Device
Henry Schein (HSIC) has become an approved supplier for DermaSensor's FDA-cleared handheld skin cancer detection device, enhancing its focus on high-margin technology and specialty offerings. While this partnership supports Henry Schein's strategic shift and potential cost savings, investors should consider ongoing pricing pressures and customer bargaining power that could affect margins. The article emphasizes that this agreement, while positive, does not significantly alter the near-term investment drivers, which include execution of its value creation program and navigating potential margin compression.
Q2 Earnings Outperformers: Align Technology (NASDAQ:ALGN) And The Rest Of The Dental Equipment & Technology Stocks
The article reviews the Q2 performance of several dental equipment and technology stocks, highlighting Align Technology (NASDAQ:ALGN) as the weakest performer against analyst estimates despite revenue growth, and Envista (NYSE:NVST) as the strongest with the fastest revenue growth. Dentsply Sirona (NASDAQ:XRAY) experienced revenue decline but beat EPS estimates, while Henry Schein (NASDAQ:HSIC) showed strong performance with significant beats on expectations. Overall, the sector saw mixed market reactions post-earnings, with most stocks declining despite many beating revenue estimates.
Hsbc Holdings PLC Buys New Holdings in Kinross Gold Corporation $KGC
HSBC Holdings PLC has acquired a new stake in Kinross Gold Corporation, purchasing 38,417 shares valued at approximately $905,000 during the second quarter. This move aligns with other institutional investors increasing their holdings, contributing to hedge funds and institutional investors owning 63.69% of the stock. Kinross Gold reported strong Q2 earnings, beating estimates with $0.71 EPS and a 29.5% year-over-year revenue increase, and maintains a "Moderate Buy" consensus rating from analysts.
Henry Schein Inc. stock outperforms competitors despite losses on the day
Shares of Henry Schein Inc. (HSIC) fell 1.43% to $88.52 on Tuesday, despite outperforming the broader market, which saw the S&P 500 Index (SPX) drop 0.71% and the Dow Jones Industrial Average (DJIA) fall 0.79%. The company's stock closed 3.97% below its 52-week high of $92.18, achieved on August 4th.
Advance Auto Parts, Inc. $AAP Stake Raised by Maple Rock Capital Partners Inc.
Maple Rock Capital Partners Inc. significantly increased its stake in Advance Auto Parts (NYSE:AAP) by 86.5% in the second quarter, now holding 2.42 million shares valued at $150.6 million. Despite this increased institutional interest, analysts maintain a cautious "Hold" rating on the stock with a consensus price target of $50.19. The company recently reported beating quarterly earnings expectations but saw a 0.5% year-over-year revenue decline and declared a $0.25 quarterly dividend.
Clear Aligners Market
The global clear aligners market is projected to grow from USD 6.09 billion in 2026 to USD 11.04 billion by 2031, exhibiting a CAGR of 12.6%. This growth is driven by increasing preference for aesthetic orthodontic treatments, advancements in digital dentistry, and expanding access to clear aligner therapy. Key market players include Align Technology, AngelAlign Technology, Envista Holdings, and Straumann Group.
Henry Schein, Inc. (HSIC) Stock Analysis: Exploring a 9.68% Upside Potential in the Medical Distribution Sector
Henry Schein, Inc. (NASDAQ: HSIC), a prominent medical distribution company, is highlighted for its strong market position and growth potential. With a current trading price of $89.52 and an average analyst target of $98.19, the stock shows a 9.68% upside potential. The analysis points to Henry Schein's diversified operations, strategic partnerships, and solid financial health as key factors for investors in the healthcare sector.
Price-Driven Insight from (HSIC) for Rule-Based Strategy
This article provides a price-driven insight for Henry Schein Inc. (HSIC) using AI models, outlining three distinct trading strategies: Position Trading, Momentum Breakout, and Risk Hedging. It identifies a strong near-term sentiment that could lead to mid-term neutrality and long-term positive bias, noting a significant risk-reward short setup. The analysis includes multi-timeframe signal analysis with support and resistance levels.
Xtant Medical Shares Surge 16% Following BioHorizons Deal to Distribute Prolifica in Dental Market
Xtant Medical shares surged 16% after securing a deal with BioHorizons for exclusive distribution of its Prolifica growth-factor technology in the U.S. and Canadian dental markets. This partnership allows Xtant to expand into a new clinical market without establishing a new sales network, despite the company's recent financial challenges, including a 35% revenue drop and a net loss in Q2 2026. While the deal's commercial economics remain undisclosed, investors are looking for specific order and margin data to validate the rally.
Henry Schein stock holds around $90 as investors weigh FY 2026 EPS guidance
Henry Schein stock is trading around $90, near its one-year high, as investors evaluate the company's FY 2026 EPS guidance. The company's internal outlook for EPS ($5.29 to $5.39) aligns closely with the analyst consensus of $5.36, indicating a "moderate buy" rating and limited but tangible upside. Institutional interest remains strong, viewing Henry Schein as a diversified healthcare holding.
Xtant Medical partners with BioHorizons for dental distribution
Xtant Medical Holdings, Inc. announced an exclusive partnership with BioHorizons, a Henry Schein, Inc. company, to distribute its allogeneic growth factor technology in the dental and oral-maxillofacial markets. The product, named Prolifica, is designed for bone healing and regeneration applications and will be sold through BioHorizons’ commercial network in the U.S. and Canada. This long-term strategic agreement combines Xtant's expertise in regenerative biologics with BioHorizons' commercial reach.
Henry Schein Market Sentiment
This article provides an overview of Henry Schein (HSIC) market sentiment, including analyst consensus, short interest, and recent analyst actions. The consensus rating is "Overweight" with an average price target of $88. The article also highlights recent insider selling activity.
BBB Foods Inc. (NYSE:TBBB) Receives Average Recommendation of "Moderate Buy" from Brokerages
BBB Foods Inc. (NYSE:TBBB) has received a consensus "Moderate Buy" rating from ten brokerages, with an average 12-month price target of $45.13. Recent positive analyst actions include HSBC, JPMorgan, and Scotiabank raising their price targets. Despite reporting a wider-than-expected quarterly loss of $0.19 per share, the company's revenue of $1.49 billion surpassed expectations, and its shares are trading near their 52-week high.
